Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.